What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Cardiovascular disease › exenatide

exenatide in cardiovascular disease

exenatide is not approved in the US for cardiovascular disease, and has 13 trials on file here in this condition. 9 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

13 registered trials study exenatide (Bydureon, Byetta) in cardiovascular disease. None has a scheduled reporting date on file.

Trials on file
13
Active
0
Active phase 3
0
Participants in active trials
0
Sponsors
12
Scheduled readouts
0

All trials on file

Every registered trial of exenatide grouped under cardiovascular disease, largest first. Grouping follows the registry’s own condition wording.

TrialStatusPhaseSponsor
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
NCT02404376
CompletedP3Hospital Universitari Vall d'Hebron Research Institute
Trial of EXenatide in Acute Ischaemic Stroke
NCT03287076
UnknownP2Neuroscience Trials Australia
Exenatide for Myocardial Protection During Reperfusion Study
NCT01938235
UnknownP2University Health Network, Toronto
Myocardial Protection of Exenatide in AMI
NCT01580514
CompletedP4Kyunghee University Medical Center
Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI
NCT00835848
CompletedP4Rigshospitalet, Denmark
Physical and Chemical Study of Atherosclerosis Mechanisms
NCT01700075
CompletedP4Nazarbayev University
Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)
NCT01254123
UnknownP3Amsterdam UMC, location VUmc
Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients
NCT00736229
CompletedP4Saint Luke's Health System
Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects
NCT02621489
CompletedP4Karolinska Institutet
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass
NCT01373216
CompletedP3Charles University, Czech Republic
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers
NCT02838589
CompletedP2Christina Kruuse
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke
NCT02829502
UnknownP2Christina Kruuse
The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults
NCT00845559
WithdrawnP4Yale University

See the full record for exenatide, or every molecule being studied in cardiovascular disease. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.